How cyclic AMP (cAMP) could positively or negatively regulate G1 phase progression in different cell types or in cancer cells versus normal differentiated counterparts has remained an intriguing question for decades. At variance with the cAMP-dependent mitogenesis of normal thyroid epithelial cells, we show here that cAMP and cAMP-dependent protein kinase activation inhibit S-phase entry in four thyroid carcinoma cell lines that harbor a permanent activation of the Raf/ERK pathway by different oncogenes. Only in Ret/PTC1-positive TPC-1 cells did cAMP markedly inhibit the Raf/ERK cascade, leading to mTOR pathway inhibition, repression of cyclin D1 and p21 and p27 accumulation. p27 knockdown did not prevent the DNA synthesis inhibition. In the other cells, cAMP little affected these signaling cascades and levels of cyclins D or CDK inhibitors. However, cAMP differentially inhibited the pRb-kinase activity and T172-phosphorylation of CDK4 complexed to cyclin D1 or cyclin D3, whereas CDK-activating kinase activity remained unaffected. At variance with current conceptions, our studies in thyroid carcinoma cell lines and previously in normal thyrocytes identify the activating phosphorylation of CDK4 as a common target of opposite cell cycle regulations by cAMP, irrespective of its impact on classical mitogenic signaling cascades and expression of CDK4 regulatory partners.
INTRODUCTIONCyclic AMP (cAMP) is the first identified intracellular mediator (second messenger) of hormone action. In the seventies and early eighties, the observation that cAMP elevations may inhibit cell proliferation in various established cell lines, mostly of tumoral origin, has prompted an intense scientific activity, even becoming the main paradigm of cell cycle regulation (Pastan and Johnson, 1974;Pastan et al., 1975;Friedman, 1976;Rebhun, 1977). More recent studies have ascribed the cell cycle inhibition by cAMP to the inhibition of several steps of the mitogenic cascades elicited by growth factors or oncogenic mutations (Roger et al., 1995;Stork and Schmitt, 2002;Dumaz and Marais, 2005). Most generally considered mechanisms include inhibition of ERK1/2 pathway by inhibitory phosphorylations of c-Raf by cAMP-dependent protein kinases (PKA; Cook and McCormick, 1993;Graves et al., 1993;Dumaz and Marais, 2003), leading to transcriptional repression of protooncogenic transcription factors (c-jun, c-myc, egr-1, . . .;Heldin et al., 1989;Mechta et al., 1989;Cowlen and Eling, 1992), repression of D-type cyclins (cyclin D1, cyclin D3; Cocks et al., 1992;Sewing et al., 1993;Ward et al., 1996;L'Allemain et al., 1997), and accumulation of the p27 kip1 CDK inhibitor Ward et al., 1996;van Oirschot et al., 2001;Kuiperij et al., 2005), which inhibits both CDK4 and CDK2 Kuiperij et al., 2005) and thus inactivating phosphorylations of pRb. Inhibition of cyclin D1-CDK4 activity by cAMP-dependent accumulation of p27 has been ascribed to p27 impairing the activating T172-phosphorylation of CDK4 by the constitutively active CDK-activating kinase (CAK, cyclin H-C...